Wasatch Advisors LP increased its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 66.9% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,768,897 shares of the biopharmaceutical company's stock after acquiring an additional 6,323,138 shares during the quarter. Wasatch Advisors LP owned 6.13% of Esperion Therapeutics worth $43,207,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of ESPR. Vanguard Group Inc. grew its holdings in Esperion Therapeutics by 23.6% in the fourth quarter. Vanguard Group Inc. now owns 14,945,454 shares of the biopharmaceutical company's stock worth $55,298,000 after purchasing an additional 2,853,005 shares during the period. Two Seas Capital LP raised its holdings in shares of Esperion Therapeutics by 22.1% during the fourth quarter. Two Seas Capital LP now owns 11,902,521 shares of the biopharmaceutical company's stock valued at $44,039,000 after purchasing an additional 2,152,797 shares during the period. Orbimed Advisors LLC acquired a new position in shares of Esperion Therapeutics during the fourth quarter valued at about $22,072,000. State Street Corp boosted its position in shares of Esperion Therapeutics by 32.4% during the 4th quarter. State Street Corp now owns 5,930,296 shares of the biopharmaceutical company's stock worth $21,942,000 after purchasing an additional 1,451,462 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Esperion Therapeutics by 20.8% during the 4th quarter. Geode Capital Management LLC now owns 5,737,651 shares of the biopharmaceutical company's stock worth $21,234,000 after purchasing an additional 986,255 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company's stock.
Insider Buying and Selling at Esperion Therapeutics
In other news, insider Benjamin Looker sold 11,824 shares of the company's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total value of $37,245.60. Following the completion of the sale, the insider owned 667,524 shares in the company, valued at $2,102,700.60. This represents a 1.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Benjamin Halladay sold 10,773 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $3.15, for a total transaction of $33,934.95. Following the completion of the sale, the chief financial officer owned 702,829 shares of the company's stock, valued at approximately $2,213,911.35. This represents a 1.51% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.60% of the stock is currently owned by company insiders.
Esperion Therapeutics Stock Up 0.6%
Shares of Esperion Therapeutics stock opened at $3.17 on Friday. The company has a market cap of $816.88 million, a PE ratio of -52.83 and a beta of 1.07. Esperion Therapeutics, Inc. has a 52 week low of $0.95 and a 52 week high of $4.18. The business has a 50 day moving average price of $2.88 and a 200-day moving average price of $3.09.
Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its earnings results on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.08). Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%. The company had revenue of $80.10 million for the quarter, compared to analysts' expectations of $84.52 million.
Wall Street Analyst Weigh In
A number of analysts recently commented on ESPR shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Esperion Therapeutics in a research report on Tuesday, April 21st. Jefferies Financial Group lowered Esperion Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, May 1st. Wall Street Zen raised Esperion Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, March 14th. Citizens Jmp downgraded Esperion Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, May 1st. Finally, HC Wainwright lowered Esperion Therapeutics from a "buy" rating to a "neutral" rating and set a $3.16 target price on the stock. in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $5.54.
Read Our Latest Report on ESPR
About Esperion Therapeutics
(
Free Report)
Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.
The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.
Read More
Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
